Pharma’s Hidden Sustainability Risk and the Supply Chain Imperative

The pharmaceutical industry has made visible strides in reducing its operational emissions—transitioning to renewable energy, modernizing manufacturing facilities, and optimizing logistics. Yet, most emissions remain outside companies’ direct control, hidden across complex supply chains. Regulators and investors are increasingly focusing on these indirect emissions, redefining how competitiveness, compliance, and capital access are evaluated. What was once considered a secondary risk is now emerging as a central strategic concern—and the time to act is rapidly narrowing.

Emissions Transparency Is Critical for Capital Access

Financial capital is increasingly tied to ESG performance. Institutional investors are actively reallocating funds toward companies with strong sustainability credentials. According to PwC’s 2022 survey, nearly 90% of investors had already divested—or intended to divest—from companies lacking robust ESG frameworks, with 78% citing regulatory exposure as a key concern. Pharma’s reliance on long-term, risk-tolerant capital for R&D pipelines, mergers, and plant upgrades makes it particularly sensitive to this trend.

ESG-aligned assets have also outperformed traditional market indices, creating a structural preference for firms with low-carbon operations. ESG performance is increasingly considered a proxy for risk management, signaling to investors which companies are prepared for long-term market and regulatory pressures.

Governments are formalizing these expectations with mandatory reporting. The EU Corporate Sustainability Reporting Directive (CSRD), effective mid-2026, requires disclosure of:

• Scope 1: Direct emissions from owned operations
• Scope 2: Indirect emissions from purchased energy
• Scope 3: Upstream and downstream emissions, typically accounting for roughly 75% of pharma’s total footprint

In the U.S., the SEC mandates Scope 1 and 2 reporting for public companies, with Scope 3 optional but increasingly considered by investors for risk assessment. Transparency on emissions, particularly Scope 3, is becoming a non-negotiable prerequisite for access to capital.

The Intersection of Carbon and Material Costs

Europe’s Emissions Trading System (ETS) caps emissions from carbon-intensive sectors such as steel, cement, aluminum, and chemicals and requires companies to purchase allowances for their emissions. Since 2021, the cap has decreased by 2.2% per year, steadily raising the carbon price. While pharmaceutical manufacturers may not be directly regulated, their suppliers—especially packaging and chemical vendors—are, and these costs inevitably flow through the supply chain.

The Carbon Border Adjustment Mechanism (CBAM), implemented in 2023, prevents “carbon leakage” by requiring importers to declare the carbon intensity of ETS-covered goods and pay corresponding carbon fees from 2026.

In effect, emissions are increasingly embedded in product costs. Companies delaying low-carbon transitions in their supply chains risk exposure to rising material costs, tighter margins, and regulatory pressures.

Packaging: A High-Impact Lever for Sustainability

Packaging contributes up to 15% of total pharma emissions, according to McKinsey 2023. By optimizing design and using low-carbon materials, companies could cut these emissions by as much as 90% by 2040, making packaging one of the most visible and actionable sustainability levers.

Traditional materials such as aluminum and fossil-based plastics have dominated due to their barrier performance, sterility, and machinability. However, these materials are increasingly costly in carbon terms: producing one tonne of fossil-based plastic emits approximately five tonnes of CO₂, while one tonne of virgin aluminum produces over 14 tonnes. CBAM currently applies to upstream materials, but experts predict it will soon cover plastics and finished products, making packaging both an environmental and financial issue.

Reducing packaging emissions through redesign, material substitution, and supplier collaboration can lower costs, improve ESG ratings, and increase access to capital. Companies that proactively manage this aspect of their supply chains are positioning themselves for long-term resilience.

Regulatory Exemptions Are Temporary

Pharma packaging currently benefits from regulatory exemptions that protect drug availability but are limited in scope.

• California’s SB 54 requires a 25% reduction in single-use plastics, 65% recycling, and 100% recyclability or compostability by 2032, with prescription drugs and regulated devices exempt.
• The EU Packaging and Packaging Waste Regulation (PPWR) targets full recyclability by 2030; medicinal packaging is exempt for now, with a review scheduled in 2035.
• In the UK, under the Extended Producer Responsibility (EPR) scheme, medical packaging receives partial relief but is not fully exempt from fees.

These exemptions are temporary. As new recyclable and biodegradable materials meet pharma-grade standards, regulatory scrutiny will increase. Early adopters will be better prepared to maintain compliance and competitive advantage.

Material Innovation for Function and Sustainability

Reducing emissions without compromising performance is the central challenge for pharma packaging. The industry is increasingly turning to mono-material, bio-based, and halogen-free alternatives:

• Mono-material blisters of polypropylene (PP) or PET simplify recycling compared to PVC-aluminum laminates.
• Bio-based plastics such as bio-PET and bio-PE use renewable feedstocks like sugarcane, lowering carbon intensity while remaining recyclable.
• PLA (polylactic acid) is biodegradable, suited for applications with less stringent barrier requirements.
• Cyclic olefin polymers (COPs) used in pre-filled syringes are lightweight, require fewer composite parts, and reduce emissions across manufacturing, sterilization, and distribution.

At ACG, these innovations are being deployed to develop recyclable, compostable, and biodegradable primary packaging. Simultaneously, emissions reductions across operations and supplier networks help decrease Scope 3 emissions, benefiting both the company and its clients.

Conclusion: Packaging as a Strategic Asset

Pharmaceutical packaging has evolved from a functional necessity into a strategic lever. It now drives ESG performance, risk management, cost efficiency, and access to sustainable capital. Scope 3 emissions and packaging waste are no longer secondary issues—they are financially material and increasingly central to regulatory compliance.

Companies that act early—redesigning packaging, adopting sustainable materials, and collaborating with suppliers—can transform regulatory obligations into competitive advantage. Those that delay risk exposure to rising costs, tighter regulations, and reduced investor confidence.

In a sector defined by precision and long product lifecycles, sustainable packaging represents not just environmental responsibility but resilience by design. By integrating low-carbon materials and circular economy principles, pharmaceutical companies can protect margins, strengthen ESG performance, and future-proof operations in an increasingly carbon-conscious world.